Difference between revisions of "Trifluridine and tipiracil (Lonsurf)"
Jump to navigation
Jump to search
m (→Also known as) |
|||
| (16 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Combination of a thymidine-based (pyrimidine) nucleoside analog, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil, at a molar ratio 1:0.5 (weight ratio 1:0.471). Tipriacil inhibits the metabolism of trifluridine by thymidine phosphorylase, which increases the exposure of cancer cells to trifluridine. The thymidine-based nucleoside analog trifluridine is incorporated into DNA and disrupts DNA synthesis and cell proliferation.<ref name=insert>[https://www.taihooncology.com/us/prescribing-information.pdf Trifluridine and tipiracil (Lonsurf) package insert]</ref><ref>[[ | + | Class/mechanism: Combination of a thymidine-based (pyrimidine) nucleoside analog, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil, at a molar ratio 1:0.5 (weight ratio 1:0.471). Tipriacil inhibits the metabolism of trifluridine by thymidine phosphorylase, which increases the exposure of cancer cells to trifluridine. The thymidine-based nucleoside analog trifluridine is incorporated into DNA and disrupts DNA synthesis and cell proliferation.<ref name=insert>[https://www.taihooncology.com/us/prescribing-information.pdf Trifluridine and tipiracil (Lonsurf) package insert]</ref><ref>[[:File:Trifluridine&tipracil.pdf | Trifluridine and tipiracil (Lonsurf) package insert (locally hosted backup)]]</ref><ref>[https://www.lonsurf.com/ Lonsurf manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[ | + | *[[Colorectal cancer]] |
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
| Line 14: | Line 14: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2015-09-22: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm463743.htm Approved] for the treatment of patients with metastatic [[colorectal cancer]] who have been previously treated with [[Regimen_classes#Fluoropyrimidine-based_regimen|fluoropyrimidine-]], [[Regimen_classes#Oxaliplatin-based_regimen| oxaliplatin-]] and [[Regimen_classes#Irinotecan-based_regimen| irinotecan-based]] chemotherapy, an [[Regimen_classes#Anti-VEGF_biologic_therapy|anti-VEGF biological therapy]], and if RAS wild-type, an [[:Category:EGFR_inhibitors|anti-EGFR therapy]]. ''(Based on RECOURSE)'' |
| − | * | + | *2019-02-22: Approved for adult patients with metastatic [[Gastric_cancer|gastric or gastroesophageal junction (GEJ) adenocarcinoma]] previously treated with at least two prior lines of chemotherapy that included a [[Regimen_classes#Fluoropyrimidine-based_regimen|fluoropyrimidine]], a [[Regimen_classes#Platinum-based_regimen|platinum]], either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. ''(New disease entity; based on TAGS)'' |
| + | *2023-08-02: Approved in combination with bevacizumab, for metastatic [[colorectal cancer]] (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. ''(Based on SUNLIGHT)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *2016-04-25: Initial authorization | ||
| + | ==History of changes in Health Canada indication== | ||
| + | *2018-01-25: Initial notice of compliance | ||
| + | ==History of changes in PMDA indication== | ||
| + | *2014-03-24: Initial approval for the treatment of unresectable advanced or recurrent [[colorectal cancer]] (for use only if refractory or intolerant to standard therapies). | ||
| + | *2015-03-20: Revised indication for the treatment of unresectable advanced or recurrent [[colorectal cancer]]. | ||
| + | *2019-08-22: New indication for the treatment of unresectable advanced or recurrent [[gastric cancer]] that have progressed after chemotherapy. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' TAS-102 | *'''Code name:''' TAS-102 | ||
| − | *'''Generic names:''' trifluridine/tipiracil, trifluridine & tipiracil | + | *'''Generic names:''' trifluridine/tipiracil, trifluridine & tipiracil, FTD-TPI |
*'''Brand name:''' Lonsurf | *'''Brand name:''' Lonsurf | ||
| Line 26: | Line 35: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| + | [[Category:Combination drugs]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | [[Category:DNA synthesis inhibitors]] | + | [[Category:Human DNA synthesis inhibitors]] |
[[Category:Fluoropyrimidines]] | [[Category:Fluoropyrimidines]] | ||
| − | [[Category: | + | [[Category:Colorectal cancer medications]] |
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
[[Category:FDA approved in 2015]] | [[Category:FDA approved in 2015]] | ||
| + | [[Category:EMA approved in 2016]] | ||
| + | [[Category:Health Canada approved in 2018]] | ||
| + | [[Category:PMDA approved in 2014]] | ||
Revision as of 11:36, 15 August 2023
General information
Class/mechanism: Combination of a thymidine-based (pyrimidine) nucleoside analog, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil, at a molar ratio 1:0.5 (weight ratio 1:0.471). Tipriacil inhibits the metabolism of trifluridine by thymidine phosphorylase, which increases the exposure of cancer cells to trifluridine. The thymidine-based nucleoside analog trifluridine is incorporated into DNA and disrupts DNA synthesis and cell proliferation.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2015-09-22: Approved for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. (Based on RECOURSE)
- 2019-02-22: Approved for adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. (New disease entity; based on TAGS)
- 2023-08-02: Approved in combination with bevacizumab, for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. (Based on SUNLIGHT)
History of changes in EMA indication
- 2016-04-25: Initial authorization
History of changes in Health Canada indication
- 2018-01-25: Initial notice of compliance
History of changes in PMDA indication
- 2014-03-24: Initial approval for the treatment of unresectable advanced or recurrent colorectal cancer (for use only if refractory or intolerant to standard therapies).
- 2015-03-20: Revised indication for the treatment of unresectable advanced or recurrent colorectal cancer.
- 2019-08-22: New indication for the treatment of unresectable advanced or recurrent gastric cancer that have progressed after chemotherapy.
Also known as
- Code name: TAS-102
- Generic names: trifluridine/tipiracil, trifluridine & tipiracil, FTD-TPI
- Brand name: Lonsurf